Abbott Q1 2021 Earnings Report
Key Takeaways
Abbott's first-quarter sales reached $10.5 billion, a 35.3% increase, driven by strong performance across all four major business segments. The company is particularly pleased with the momentum of recently launched products and forecasts over 35% EPS growth for the year.
Worldwide sales increased by 35.3% on a reported basis and 32.9% on an organic basis.
Diagnostics sales surged by 119.8%, fueled by COVID-19 testing demand.
Medical Devices sales grew by 13.1%, driven by recovery from the COVID-19 pandemic.
Company forecasts more than 35 percent EPS growth for the year.
Abbott
Abbott
Forward Guidance
Abbott projects 2021 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of at least $3.74. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $5.00 for full-year 2021.